TY - JOUR
T1 - Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction
AU - Senatorov, Vladimir V.
AU - Friedman, Aaron R.
AU - Milikovsky, Dan Z.
AU - Ofer, Jonathan
AU - Saar-Ashkenazy, Rotem
AU - Charbash, Adiel
AU - Jahan, Naznin
AU - Chin, Gregory
AU - Mihaly, Eszter
AU - Lin, Jessica M.
AU - Ramsay, Harrison J.
AU - Moghbel, Ariana
AU - Preininger, Marcela K.
AU - Eddings, Chelsy R.
AU - Harrison, Helen V.
AU - Patel, Rishi
AU - Shen, Yizhuo
AU - Ghanim, Hana
AU - Sheng, Huanjie
AU - Veksler, Ronel
AU - Sudmant, Peter H.
AU - Becker, Albert
AU - Hart, Barry
AU - Rogawski, Michael A.
AU - Dillin, Andrew
AU - Friedman, Alon
AU - Kaufer, Daniela
N1 - Publisher Copyright: Copyright © 2019 The Authors,
PY - 2019/12/4
Y1 - 2019/12/4
N2 - Aging involves a decline in neural function that contributes to cognitive impairment and disease. However, the mechanisms underlying the transition from a young-and-healthy to aged-and-dysfunctional brain are not well understood. Here, we report breakdown of the vascular blood-brain barrier (BBB) in aging humans and rodents, which begins as early as middle age and progresses to the end of the life span. Gain-of-function and loss-of-function manipulations show that this BBB dysfunction triggers hyperactivation of transforming growth factor–β (TGFβ) signaling in astrocytes, which is necessary and sufficient to cause neural dysfunction and age-related pathology in rodents. Specifically, infusion of the serum protein albumin into the young rodent brain (mimicking BBB leakiness) induced astrocytic TGFβ signaling and an aged brain phenotype including aberrant electrocorticographic activity, vulnerability to seizures, and cognitive impairment. Furthermore, conditional genetic knockdown of astrocytic TGFβ receptors or pharmacological inhibition of TGFβ signaling reversed these symptomatic outcomes in aged mice. Last, we found that this same signaling pathway is activated in aging human subjects with BBB dysfunction. Our study identifies dysfunction in the neurovascular unit as one of the earliest triggers of neurological aging and demonstrates that the aging brain may retain considerable latent capacity, which can be revitalized by therapeutic inhibition of TGFβ signaling.
AB - Aging involves a decline in neural function that contributes to cognitive impairment and disease. However, the mechanisms underlying the transition from a young-and-healthy to aged-and-dysfunctional brain are not well understood. Here, we report breakdown of the vascular blood-brain barrier (BBB) in aging humans and rodents, which begins as early as middle age and progresses to the end of the life span. Gain-of-function and loss-of-function manipulations show that this BBB dysfunction triggers hyperactivation of transforming growth factor–β (TGFβ) signaling in astrocytes, which is necessary and sufficient to cause neural dysfunction and age-related pathology in rodents. Specifically, infusion of the serum protein albumin into the young rodent brain (mimicking BBB leakiness) induced astrocytic TGFβ signaling and an aged brain phenotype including aberrant electrocorticographic activity, vulnerability to seizures, and cognitive impairment. Furthermore, conditional genetic knockdown of astrocytic TGFβ receptors or pharmacological inhibition of TGFβ signaling reversed these symptomatic outcomes in aged mice. Last, we found that this same signaling pathway is activated in aging human subjects with BBB dysfunction. Our study identifies dysfunction in the neurovascular unit as one of the earliest triggers of neurological aging and demonstrates that the aging brain may retain considerable latent capacity, which can be revitalized by therapeutic inhibition of TGFβ signaling.
UR - http://www.scopus.com/inward/record.url?scp=85075985510&partnerID=8YFLogxK
U2 - https://doi.org/10.1126/scitranslmed.aaw8283
DO - https://doi.org/10.1126/scitranslmed.aaw8283
M3 - Article
C2 - 31801886
SN - 1946-6234
VL - 11
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 521
M1 - eaaw8283
ER -